AR016453A1 - Pirazolopirimidinas y perazolotriazinas, un procedimiento para su preparacion, medicamentos y el uso de las mismas para la elaboracion de los medicamentos - Google Patents
Pirazolopirimidinas y perazolotriazinas, un procedimiento para su preparacion, medicamentos y el uso de las mismas para la elaboracion de los medicamentosInfo
- Publication number
- AR016453A1 AR016453A1 ARP990100990A ARP990100990A AR016453A1 AR 016453 A1 AR016453 A1 AR 016453A1 AR P990100990 A ARP990100990 A AR P990100990A AR P990100990 A ARP990100990 A AR P990100990A AR 016453 A1 AR016453 A1 AR 016453A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- optionally substituted
- morpholinyl
- preparation
- alkyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 2
- 229940079593 drug Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- -1 methylpiperazinyl Chemical group 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004193 piperazinyl group Chemical group 0.000 abstract 2
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 abstract 1
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- PEYVWBGHBCDXRT-UHFFFAOYSA-N N1=NNC2=CN=NC2=C1 Chemical class N1=NNC2=CN=NC2=C1 PEYVWBGHBCDXRT-UHFFFAOYSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- 125000003944 tolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Pirazolopirimidinas y pirazolotriazinas,que comprende compuestos de formula general(I),en donde R1 significa fenilo, opcionalmente sustituido con uno o másalquilo inferior,halogeno, alcoxilo inferior, tolilo, piridilo, naftilo tiofenilo; R2 significahidrogeno, alquilo inferior, tioalquilo inferior o hidroxilo-alcoxilo inferior, R3 significa amino, alquilamino inferior, di-aquilo inferior-amino, piperazinilo opcionalmente sustituido con uno o más alquilo inferior,bencilo, fenilo o hidroxialquiloinferior, morfolinilo, imidalilo, (CH3)2N(CH2)NNH-, (CH3)2N(CH2)nO, morfolinilo-(CH2)nO en donde n significa 2 o 3; R4significa hidrogeno, alquilo inferior o hidroxi-alquilo inferior, R5 significa hidrogeno, halogeno, alquilo inferior, cicloalquilode 3 a 6 átomos de carbono,alquilo inferior-alcoxilo inferior, hidroxiloalquilo inferior alcoxi inferior, (CH3)2N(CH2)nNH-, piperazinilo, opcionalmente sustituido con alquilo inferior,metilpiperazinilo, opcionalmente sustituido con alquilo inferior,morfolinilo, metilmorfolinilo, dialquilamino inferior o di-alquilamino inferior-alquiloinferior, o R4 y R5 juntos, significan un grupo -(CH2)m- o -CH2-S-CH2- con m=3 o 4, así como sus sales farmacéuticamente aceptables. Sorprendentemente, estoscompuestos tienen una afinidad selectiva para los receptores de 5HT-6. Son convenientemente adecuados para el tratamiento y prevencion de trastornos nerviososcentrales tales como por ejemplo: psicosis, esquizofrenia, depresiones maníacas, depresiones, trastornos neurologicos, trastornos de la memoria, enfermedad deParkinson, esclerosis lateral amiotrofica, enfermedad de Alzheimer y corea de Huntington.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98104346 | 1998-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR016453A1 true AR016453A1 (es) | 2001-07-04 |
Family
ID=8231568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990100990A AR016453A1 (es) | 1998-03-11 | 1999-03-09 | Pirazolopirimidinas y perazolotriazinas, un procedimiento para su preparacion, medicamentos y el uso de las mismas para la elaboracion de los medicamentos |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US6194410B1 (es) |
| EP (1) | EP0941994B1 (es) |
| JP (1) | JP3231288B2 (es) |
| KR (1) | KR100313181B1 (es) |
| CN (1) | CN1118468C (es) |
| AR (1) | AR016453A1 (es) |
| AT (1) | ATE240332T1 (es) |
| AU (1) | AU752408B2 (es) |
| BR (1) | BR9901095A (es) |
| CA (1) | CA2265095C (es) |
| CZ (1) | CZ291514B6 (es) |
| DE (1) | DE69907784T2 (es) |
| DK (1) | DK0941994T3 (es) |
| ES (1) | ES2198095T3 (es) |
| HR (1) | HRP990077B1 (es) |
| HU (1) | HUP9900589A1 (es) |
| ID (1) | ID23575A (es) |
| IL (1) | IL128869A (es) |
| MA (1) | MA26612A1 (es) |
| MY (1) | MY119536A (es) |
| NO (1) | NO312297B1 (es) |
| NZ (1) | NZ334526A (es) |
| PE (1) | PE20000337A1 (es) |
| PL (1) | PL331875A1 (es) |
| PT (1) | PT941994E (es) |
| RU (1) | RU2218340C2 (es) |
| SG (1) | SG78336A1 (es) |
| SI (1) | SI0941994T1 (es) |
| TR (1) | TR199900531A3 (es) |
| TW (1) | TW585865B (es) |
| UY (1) | UY25419A1 (es) |
| YU (1) | YU12099A (es) |
| ZA (1) | ZA991946B (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000059907A2 (en) * | 1999-04-06 | 2000-10-12 | Du Pont Pharmaceuticals Company | Pyrazolotriazines as crf antagonists |
| DE19956791A1 (de) * | 1999-11-25 | 2001-05-31 | Merck Patent Gmbh | Neue Sulfonyloxazolamine |
| PE20020394A1 (es) | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
| IL157615A0 (en) * | 2001-03-13 | 2004-03-28 | Bristol Myers Squibb Co | 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| YU96103A (sh) | 2001-06-07 | 2006-08-17 | F.Hoffmann-La Roche Ag. | Novi derivati indola sa afinitetom za 5-ht6 receptor |
| ATE331707T1 (de) | 2001-06-15 | 2006-07-15 | Hoffmann La Roche | 4 piperazinylindolderivate mit affinität zum 5- ht6-rezeptor |
| WO2003013510A1 (en) * | 2001-08-07 | 2003-02-20 | Smithkline Beecham P.L.C. | 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
| IL162243A0 (en) * | 2001-12-20 | 2005-11-20 | Wyeth Corp | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
| US6642381B2 (en) * | 2001-12-27 | 2003-11-04 | Hoffman-La Roche Inc. | Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors |
| GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| UA78999C2 (en) * | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
| US6875771B2 (en) | 2002-07-26 | 2005-04-05 | Bristol-Myers Squibb Company | Pyridopyrimidine derivatives as 5-HT6 antagonists |
| US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| EP2194058B1 (en) * | 2002-09-04 | 2013-11-27 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidines suitable for the treatment of cancer diseases |
| US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| JP2006517966A (ja) * | 2003-02-14 | 2006-08-03 | ワイス | ５−ヒドロキシトリプタミン−６リガンドとしてのヘテロサイクリル−３−スルホニルアザインドールまたは−アザインダゾール誘導体 |
| MXPA05008955A (es) | 2003-02-28 | 2006-02-22 | Teijin Pharma Ltd | Derivados de pirazolo [1,5-a] pirimidina. |
| GB0305559D0 (en) * | 2003-03-11 | 2003-04-16 | Teijin Ltd | Compounds |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| WO2005112936A1 (en) * | 2004-05-14 | 2005-12-01 | The Regents Of The University Of Michigan | Compositions and methods relating to protein kinase inhibitors |
| KR20070090172A (ko) * | 2004-11-04 | 2007-09-05 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나아제의 억제제로서 유용한피라졸로[1,5-ａ]피리미딘 |
| RU2390523C2 (ru) * | 2005-10-21 | 2010-05-27 | Мицубиси Танабе Фарма Корпорейшн | ПРОИЗВОДНОЕ ПИРАЗОЛ[1,5-a]ПИРИМИДИНА |
| RU2330854C2 (ru) * | 2006-03-15 | 2008-08-10 | Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУВПО "ПГФА Росздрава") | Способ получения конденсированных гем-диметилзамещенных амино-1,3,5-триазинов |
| RU2369600C1 (ru) * | 2008-01-24 | 2009-10-10 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| WO2009093210A2 (ru) | 2008-01-24 | 2009-07-30 | Alla Chem, Llc | ЗАМЕЩЕННЫЕ ЦИKЛOAЛKAHO[e ИЛИ d]ПИPAЗOЛO[l,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| EA017805B1 (ru) * | 2008-01-24 | 2013-03-29 | Андрей Александрович ИВАЩЕНКО | 2-АЛКИЛАМИНО-3-АРИЛСУЛЬФОНИЛЦИКЛОАЛКАНО[e ИЛИ d]ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| EA017968B1 (ru) | 2008-01-24 | 2013-04-30 | Андрей Александрович ИВАЩЕНКО | ЗАМЕЩЕННЫЕ 2-АМИНО-3-СУЛЬФОНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ-АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| RU2384581C2 (ru) | 2008-05-07 | 2010-03-20 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 2-АМИНО-3-СУЛЬФОНИЛ-ТЕТРАГИДРО-ПИРАЗОЛО[1,5-a]ПИРИДО-ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| CA2755968C (en) * | 2008-10-06 | 2019-03-19 | Andrey Alexandrovich Ivashchenko | Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-ht6 receptor antagonists and methods for the production and use thereof |
| AR074231A1 (es) | 2008-11-27 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de 6, 7, 8, 9-tetrahidro-5h-1, 4, 7, 10a-tetraaza-ciclohept[f]indeno, composiciones farmacéuticas que contienen estos compuestos, su uso en el agonismo del receptor 5-ht2c y procesos para prepararlos. |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| BR112013011737A2 (pt) | 2010-11-15 | 2016-08-09 | Univ Leuven Kath | composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv |
| RU2443697C1 (ru) | 2010-12-21 | 2012-02-27 | Александр Васильевич Иващенко | Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения |
| MX342177B (es) | 2011-09-30 | 2016-09-20 | Ipsen Pharma Sas | Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica. |
| MX381849B (es) * | 2012-03-09 | 2025-03-13 | Lexicon Pharmaceuticals Inc | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso. |
| TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| TW201620911A (zh) * | 2014-03-17 | 2016-06-16 | 雷西肯製藥股份有限公司 | 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法 |
| CA2960777A1 (en) | 2014-09-17 | 2016-03-24 | Oncodesign S.A. | Macrocyclic lrrk2 kinase inhibitors |
| CA2978170C (en) | 2015-03-09 | 2024-02-27 | Aurigene Discovery Technologies Limited | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors |
| WO2017052394A1 (en) * | 2015-09-23 | 2017-03-30 | Uniwersytet Jagielloński | Imidazopyridine compounds and their use as 5-ht6 receptor ligands |
| HK1256751A1 (zh) | 2015-11-02 | 2019-10-04 | Janssen Pharmaceutica Nv | [1，2，4]三唑并[1，5-a]嘧啶-7-基化合物 |
| TWI764950B (zh) | 2016-11-02 | 2022-05-21 | 比利時商健生藥品公司 | Ｐｄｅ２抑制劑 |
| EA039102B1 (ru) | 2016-11-02 | 2021-12-03 | Янссен Фармацевтика Нв | Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2 |
| ES2912264T3 (es) | 2016-11-02 | 2022-05-25 | Janssen Pharmaceutica Nv | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2 |
| US20220296595A1 (en) | 2019-05-05 | 2022-09-22 | Qilu Regor Therapeutics Inc. | Cdk inhibitors |
| CN112142744A (zh) * | 2019-06-28 | 2020-12-29 | 上海瑛派药业有限公司 | 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用 |
| CN115209952B (zh) | 2020-01-13 | 2025-05-30 | 维基分析有限公司 | 经取代的吡唑并嘧啶及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3907799A (en) * | 1971-08-16 | 1975-09-23 | Icn Pharmaceuticals | Xanthine oxidase inhibitors |
| WO1989000994A2 (en) | 1987-07-31 | 1989-02-09 | E.I. Du Pont De Nemours And Company | Herbicidal sulfonamides |
| US4921527A (en) * | 1987-07-31 | 1990-05-01 | E. I. Du Pont De Nemours And Company | Herbicidal sulfonamides |
| DE3825043A1 (de) | 1988-07-20 | 1990-02-15 | Schering Ag | 3-methylsulfonyl-pyrazolo(1,5-a)pyrimidin-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, pflanzenwuchsregulierender und fungizider wirkung |
| US5571813A (en) * | 1993-06-10 | 1996-11-05 | Beiersdorf-Lilly Gmbh | Fused pyrimidine compounds and their use as pharmaceuticals |
| WO1997011075A1 (en) | 1995-09-22 | 1997-03-27 | Takeda Chemical Industries, Ltd. | Triazole compounds, their production and use |
| CA2274055A1 (en) | 1996-12-19 | 1998-06-25 | Smithkline Beecham P.L.C. | N-piperazin-1-ylphenyl-benzamide derivatives |
| DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| WO1999002502A2 (en) | 1997-07-11 | 1999-01-21 | Smithkline Beecham Plc | Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation |
-
1999
- 1999-02-24 US US09/256,927 patent/US6194410B1/en not_active Expired - Fee Related
- 1999-03-03 EP EP99102872A patent/EP0941994B1/en not_active Expired - Lifetime
- 1999-03-03 PT PT99102872T patent/PT941994E/pt unknown
- 1999-03-03 DK DK99102872T patent/DK0941994T3/da active
- 1999-03-03 AT AT99102872T patent/ATE240332T1/de not_active IP Right Cessation
- 1999-03-03 DE DE69907784T patent/DE69907784T2/de not_active Expired - Fee Related
- 1999-03-03 ES ES99102872T patent/ES2198095T3/es not_active Expired - Lifetime
- 1999-03-03 SI SI9930320T patent/SI0941994T1/xx unknown
- 1999-03-08 IL IL12886999A patent/IL128869A/xx not_active IP Right Cessation
- 1999-03-08 PE PE1999000183A patent/PE20000337A1/es not_active Application Discontinuation
- 1999-03-08 NZ NZ334526A patent/NZ334526A/xx unknown
- 1999-03-08 YU YU12099A patent/YU12099A/sh unknown
- 1999-03-08 CA CA002265095A patent/CA2265095C/en not_active Expired - Fee Related
- 1999-03-08 MA MA25485A patent/MA26612A1/fr unknown
- 1999-03-09 JP JP06114999A patent/JP3231288B2/ja not_active Expired - Fee Related
- 1999-03-09 UY UY25419A patent/UY25419A1/es unknown
- 1999-03-09 SG SG1999001080A patent/SG78336A1/en unknown
- 1999-03-09 AR ARP990100990A patent/AR016453A1/es unknown
- 1999-03-09 MY MYPI99000853A patent/MY119536A/en unknown
- 1999-03-10 ID IDP990198D patent/ID23575A/id unknown
- 1999-03-10 ZA ZA9901946A patent/ZA991946B/xx unknown
- 1999-03-10 HU HU9900589A patent/HUP9900589A1/hu not_active Application Discontinuation
- 1999-03-10 RU RU99105137/04A patent/RU2218340C2/ru active
- 1999-03-10 KR KR1019990007881A patent/KR100313181B1/ko not_active Expired - Fee Related
- 1999-03-10 PL PL99331875A patent/PL331875A1/xx unknown
- 1999-03-10 CZ CZ1999825A patent/CZ291514B6/cs not_active IP Right Cessation
- 1999-03-10 NO NO19991150A patent/NO312297B1/no unknown
- 1999-03-10 TW TW088103692A patent/TW585865B/zh not_active IP Right Cessation
- 1999-03-10 BR BR9901095-0A patent/BR9901095A/pt not_active Application Discontinuation
- 1999-03-11 CN CN99105964A patent/CN1118468C/zh not_active Expired - Fee Related
- 1999-03-11 TR TR1999/00531A patent/TR199900531A3/tr unknown
- 1999-03-11 AU AU20383/99A patent/AU752408B2/en not_active Ceased
- 1999-03-11 HR HR990077A patent/HRP990077B1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR016453A1 (es) | Pirazolopirimidinas y perazolotriazinas, un procedimiento para su preparacion, medicamentos y el uso de las mismas para la elaboracion de los medicamentos | |
| SV1999000141A (es) | Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos ref. pc10411abcz/bb | |
| PA8575401A1 (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso | |
| TR200201026T2 (tr) | Benzodiazepin türevleri | |
| SV1999000016A (es) | Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv | |
| BR9106665A (pt) | Derivados de quinuclidina | |
| DK0876818T3 (da) | Middel til behnadling af nerodegenerative lidelser | |
| BG104561A (en) | Aryl fused azapolycyclic compounds | |
| AR014313A1 (es) | Derivados de benzosulfona, medicamento que los contiene, procedimiento para su preparacion y su empleo para la manufactura de dicho medicamento | |
| ATE160774T1 (de) | Antipsychotische benzimidazolderivate | |
| ES2113368T3 (es) | Antagonistas de serotonina. | |
| FI970150A0 (fi) | Substituoituja pyrimidiiniyhdisteitä ja niiden käyttö | |
| AR029454A1 (es) | Derivados de piperazina sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos | |
| SE9702564D0 (sv) | New compounds | |
| EE200300167A (et) | Amidoalküülpiperidiini ja -piperasiini derivaadid, neid sisaldav farmatseutiline kompositsioon ningühendite kasutamine närvisüsteemi häirete raviks | |
| AR024847A1 (es) | 4-alquenil y 4-alquinil oxindoles, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento. | |
| ES2084996T3 (es) | Piperazinas sustituidas utiles como agentes para el sistema nervioso central. | |
| CY1106257T1 (el) | ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΙΔΑΖΙΝΟ [4,5-(b)]-ΙΝΔΟΛΗ -1-ΑΚΕΤΑΜΙΔΗ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΣΚΕΥΑΣΜΑΤΩΝ ΠΟΥ ΠΡΟΟΡΙΖΟΝΤΑΙ ΓΙΑ ΝΟΣΟΥΣ ΠΟΥ ΣΥΝΔΕΟΝΤΑΙ ΜΕ ΤΗ ΔΥΣΛΕΙΤΟΥΡΓΙΑ ΤΩΝ ΥΠΟΔΟΧΕΩΝ ΠEPΙΦEPΙΚΟΥ ΤΥΠΟΥ ΣΤΙΣ ΒΕΝΖΟΔΙΑΖΕΠΙΝΕΣ | |
| ATE180781T1 (de) | Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung | |
| PE20061318A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos | |
| TR200003122T2 (tr) | Aril bağlı azapolisiklik bileşikler | |
| SE9702563D0 (sv) | Compounds | |
| FI971310A0 (fi) | 2,7-substituoituja oktahydro-1H-pyrido/1,2-a/pyratsiinijohdannaisia | |
| GB9318691D0 (en) | Therapeutic agents | |
| AR025379A1 (es) | 9a-azalidas con actividad antibacteriana. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |